Table 3. Proportion of patients under and above different thresholds of TTR and its association with CTEPH after the first available VTE.

	Patients with CTEPH (%)	Patients without CTEPH (%)	Odds ratio (95% CI)	Odds ratio (95%CI)*	Odds ratio (95%CI)**
3-month analysis	n = 44	n = 147
≥ 50%	35 (80)	119 (81)	1.0 (ref)	1.0 (ref)	1.0 (ref)
< 50%	9 (20)	28 (19)	1.1 (0.5 to 2.5)	1.1 (0.4 to 2.6)	1.1 (0.4 to 3.0)
6-month analysis	n = 44	n = 150
≥ 50%	39 (89)	137 (91)	1.0 (ref)	1.0 (ref)	1.0 (ref)
< 50%	5 (11)	13 (9)	1.4 (0.5 to 4.0)	1.3 (0.4 to 4.2)	0.6 (0.1 to 2.3)
3-month analysis	n = 44	n = 147
≥ 60%	29 (66)	108 (73)	1.0 (ref)	1.0 (ref)	1.0 (ref)
< 60%	15 (34)	39 (27)	1.4 (0.7 to 3.0)	1.5 (0.7 to 3.3)	1.4 (0.6 to 3.2)
6-month analysis	n = 44	n = 150
≥ 60%	31 (70)	126 (84)	1.0 (ref)	1.0 (ref)	1.0 (ref)
< 60%	13 (30)	24 (16)	2.2 (1.01 to 4.8)	2.1 (0.9 to 5.0)	1.4 (0.6 to 3.3)
3-month analysis	n = 44	n = 147
≥ 70%	27 (61)	93 (63)	1.0 (ref)	1.0 (ref)	1.0 (ref)
< 70%	17 (39)	54 (37)	1.1 (0.5 to 2.2)	1.2 (0.5 to 2.4)	1.3 (0.5 to 2.9)
6-month analysis	n = 44	n = 150
≥ 70%	25 (57)	103 (69)	1.0 (ref)	1.0 (ref)	1.0 (ref)
< 70%	19 (43)	47 (31)	1.7 (0.8 to 3.3)	1.8 (0.9 to 3.8)	1.8 (0.8 to 4.1)

^{^} Showing data of patients with an initial acute PE, of which in 9 patients INR data was only available from recurrent VTE, i.e. 6 recurrent PE and 3 DVT episodes.

*Adjusted for age and sex.

**Adjusted for age, sex and type of VKA.

Abbreviations: CTEPH, chronic thromboembolic pulmonary hypertension; VTE, venous thromboembolism; TTR, time in therapeutic range; PE, pulmonary embolism; DVT, deep vein thrombosis; VKA; vitamin K antagonist.